Deltex Medical (GB:DEMG) has released an update.
Deltex Medical Group PLC, the leader in Oesophageal Doppler Monitoring, has reported strong progress with its new TrueVue monitor across the UK, EU, and other regions recognizing CE marking, with increasing orders and ongoing legacy device revenue maximization. The company is also advancing with registrations in the USA, Asia, and Latin America, expecting USA sales to start in 2025, and is developing an innovative non-invasive device to expand its market reach. Optimistic about meeting its quarterly targets, Deltex Medical is poised for a positive year ahead.
For further insights into GB:DEMG stock, check out TipRanks’ Stock Analysis page.
